Mer­ck eats the lunch Bris­tol My­ers nev­er served, win­ning TMB-based OK for Keytru­da

Bris­tol My­ers Squibb might have pop­u­lar­ized the con­cept of us­ing tu­mor mu­ta­tion­al bur­den to iden­ti­fy pa­tients most like­ly to ben­e­fit from check­point in­hibitors, but Mer­ck …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER